Sensipar Is "Major Breakthrough" For Secondary Hyperparathyroidism – FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA views Amgen’s Sensipar as a significant therapeutic advance for secondary hyperparathyroidism, NDA review documents state.